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We prospectively determined the prevalence of community-associated Staphylococcus aureus in a large cystic
fibrosis (CF) center between October 2005 and October 2007. We found that 2.7% (19/707) of the CF patients
who had cultures during the study period were infected with this organism, representing 14% of the total
methicillin-resistant Staphylococcus aureus strains (n  140) recovered from the patient population during the
study period.
Community-associated methicillin-resistant Staphylococcus
aureus (CA-MRSA) has recently emerged as an important
human pathogen (6, 9, 11, 17). CA-MRSA is characterized by
the presence of the mecA gene on a small mobile staphylococ-
cal cassette chromosome (SCC) designated as SCCmec type IV
(11). In addition, the CA-MRSA strains harbor unique viru-
lence factors, such as Panton-Valentine leukocidin (PVL) (17).
PVL is a two-component pore-forming toxin complex encoded
by two cotranscribed genes (lukS-PV and lukF-PV) that cause
tissue necrosis and leukocyte destruction (5, 14, 15). One of the
most striking features of this pathogen is its association with
necrotizing pneumonia (6). S. aureus is typically the first bac-
terial pulmonary pathogen recognized in cystic fibrosis (CF)
patients, resulting in chronic S. aureus infection that can persist
for years. The specter of a highly virulent S. aureus strain,
which has been reported to cause necrotizing pneumonia in a
small number of CF patients (4), is a huge concern.
According to the Cystic Fibrosis Foundation patient registry,
there was a significant rise in MRSA infection among CF
patients, from 0.1% in 1995 to 18.9% in 2006 (2, 7). A recent
10-year cohort study of over 1,700 children and adults with CF
showed that persistent MRSA infection was associated with a
more rapid decline in lung function as measured by forced
expiratory volume in 1 s (often referred to as “FEV1”) (3). Less
is known about the importance of CA-MRSA in CF patients.
Though CA-MRSA has been detected in respiratory cultures
of CF patients (4, 7), its persistence and frequency are unclear.
The purpose of this 2-year prospective study was to deter-
mine the frequency with which CA-MRSA is found and ac-
quired in our CF population as well as how long it persists and
if specific clones of the organism are being spread among our
patients. This study also provides the framework for future
studies to determine the impact of CA-MRSA on the lung
function of CF patients.
(A preliminary report of this work was presented previously
by J. S. Goodrich, T. N. Sutton-Shields, J. P. Wedd, M. B.
Miller, and P. H. Gilligan at the 107th General Meeting of the
American Society for Microbiology, 2007 [8].)
During this longitudinal study at the Clinical Microbiology-
Immunology Laboratories at the University of North Carolina
Hospitals (Chapel Hill, NC) from 19 October 2005 to 19 Oc-
tober 2007, 5,265 respiratory cultures from 707 CF patients
were screened for MRSA. Respiratory samples were plated
onto horse blood, colistin nalidixic acid, MacConkey, mannitol
salt, and Burkholderia cepacia selective agar plates. Isolates
were identified as MRSA based on a positive tube coagulase
test or a positive BactiStaph (Remel, Lenexa, KS) latex agglu-
tination test, and susceptibility tests were performed by Kirby-
Bauer disk diffusion following CLSI guidelines (1). Of these
cultures, 13% (n  662) contained MRSA. These MRSA-
positive cultures were collected from respiratory samples from
140 patients; thus, 20% of CF patients harbor MRSA.
To determine if these MRSA isolates were hospital associ-
ated (SCCmec type II and PVL negative) or community asso-
ciated (SCCmec type IV and PVL positive), molecular char-
acterization was performed. The presence of PVL was assessed
using real-time PCR assays targeting pvlS and pvlF (12) and
the intergenic region between pvlS and pvlF. The assay was
done using 200 nM of the probe (5 FAM-CTC ATG AAA
TTA AAG TGA AAG GAC-TAMRA, where FAM is 6-car-
boxyfluorescein and TAMRA is 6-carboxytetramethylrhod-
amine) and 900 nM of each primer (forward, 5 AAC AGA
AAT TAC ACA GTT A; reverse, 5 ATT GAT GTA ACA
ACT GAT GAT). Using an ABI 7500 instrument (Applied
Biosystems, Foster City, CA), the following cycling parameters
were employed: 50°C for 2 min; 95°C for 10 min; 45 cycles of
95°C for 15 s, 55°C for 30 s, and 72°C for 35 s.
The SCCmec types were identified using a previously pub-
lished protocol (13).
Isolates from MRSA-positive patients were molecularly an-
alyzed at 2-month intervals to determine the persistence or
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acquisition of CA-MRSA. Depending on the cultures collected
during the 2-year period, 1 to 10 isolates were screened per
patient, resulting in the molecular characterization of 470 iso-
lates. Of these isolates, 10% (n  47) contained genes for PVL.
All PVL-positive isolates harbored SCCmec type IV. PVL-
negative MRSA isolates (n  423) were characterized as fol-
lows: 89% (n  378) contained SCCmec type II, 1% (n  3)
contained SCCmec type III, and 10% (n  42) harbored
SCCmec type IV. Based on either the most frequently isolated
or the final isolate from each patient, 14% (n  19) of the
patients screened were positive for MRSA that harbors PVL,
while 86% (n  121) were not positive for PVL. Considering
the PVL status and SCCmec type, the majority of the MRSA-
positive patients maintained the same organism for the dura-
tion of the study with the exception of four patients. Two
patients with PVL-negative SCCmec type II MRSA acquired
PVL-negative, SCCmec type IV MRSA. One patient had
SCCmec type III and acquired SCCmec type II. Finally, one
patient initially had a PVL-negative, SCCmec type II MRSA
isolate but acquired a PVL-positive, SCCmec type IV MRSA
strain. Defining CA-MRSA as those isolates of MRSA that
harbor PVL and SCCmec type IV, the prevalence of CA-
MRSA among CF patients screened during this 24-month pe-
riod was 2.7% (19/707).
The persistence of the CA-MRSA infections as chronic or
transient was determined. Chronic infection is defined as hav-
ing three or more cultures containing MRSA during the study
period, with the most recent culture still positive. Transient
infection is defined as having one or more positive CA-MRSA
culture(s) followed by at least three subsequent negative cul-
tures. Of the patients with CA-MRSA infection, 32% (n  6)
were chronically infected, 26% (n  5) were transiently in-
fected, and the chronicity of infection could not be determined
for 42% (n  8) because too few cultures had been collected.
Interestingly, one chronically infected patient had hospital-
associated MRSA and acquired CA-MRSA during the study
period.
Pulsed-field gel electrophoresis analysis reveals that both
MRSA strains USA300 and USA400 entered our CF popula-
tion before the study. One isolate per culture from each patient
with CA-MRSA was analyzed (n  47), resulting in one to six
isolates per patient, depending on the number of cultures ob-
tained. Pulsed-field gel electrophoresis was performed, and the
results were interpreted as previously described (10, 16). Band-
ing patterns were compared to prototype USA300 and
USA400 clones. Eighty-nine percent (n  17) of the CA-
MRSA-positive patients have USA300 or a closely related
clone, 5% (n  1) have USA400, and 5% (n  1) have a
unique clone. As the majority of the clones are similar to
USA300 and USA400, which are commonly found in the gen-
eral population (10, 17), and a specific unique clone is not
found in multiple patients, it is not possible to determine if
there was patient-to-patient spread among CF patients.
The emergence of CA-MRSA in the CF population has
been described previously (4, 7), but our prospective study
following an entire CF clinic population (n  707) for 24
months has allowed us to examine the epidemiology of this
organism longitudinally. Several observations were possible.
First, approximately 20% of our CF population harbors
MRSA. This number is consistent with the 18.9% national
MRSA infection rate among CF patients (2). Like Elizur et al.
(4), we found that approximately 10% of the MRSA isolates
recovered during our study period were CA-MRSA. We found
that persistence of the CA-MRSA clone was similar to that of
other MRSA clones in the CF patient population (3). While
the source of the clones infecting the CF population is un-
known, there is no evidence of the spread of a CA-MRSA
clone unique to the CF population in our center.
Acquisition of this potentially virulent strain was an unusual
clinical event; it was seen in only 2% (n  13) of the CF
patients during the 2-year study that included 707 patients. Of
the patients with PVL-positive strains, 12 had at least two
MRSA-negative cultures prior to acquiring a PVL-positive
MRSA isolate, and one had a PVL-negative MRSA isolate
prior to obtaining a PVL-positive one. Four percent (n  29)
of all CF patients acquired PVL-negative MRSA during the
course of the study. Assuming that each patient was infected
with only one strain of CA-MRSA at any given time, our data
suggest that in the CF lung environment, the USA300 and
USA400 clones are no more fit than are other MRSA clones.
However, if a patient was colonized simultaneously with mul-
tiple strains of MRSA, this may not have been detected in our
analysis, as only one isolate was screened per culture.
The importance of CA-MRSA in CF lung disease is uncer-
tain. Elizur et al. (4) described two CF patients with cavitary
lesions associated with PVL-positive MRSA. This observation
is consistent with other reports of serious pulmonary manifes-
tations of CA-MRSA infection (6). On the other hand, Glik-
man and colleagues (7) did not find an association between
CA-MRSA with either pulmonary exacerbation or necrotizing
pneumonia. In the 19 patients seen here with CA-MRSA in-
fection, there were no episodes of necrotizing pneumonia (M.
Muhlebach, personal communication). The paucity of data on
the clinical outcome of CF patients infected with CA-MRSA
suggests a need for a well-controlled, multicenter study to
assess the impact of this organism on CF lung disease, which is
currently ongoing.
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